Why the study?
Whether epigallocatechin gallate (EGCG) alleviates myocardial ischemia-reperfusion (I/R) injury by regulating ferroptosis and its underlying mechanism were unclear.
Population
H9c2 cardiomyocytes and rats subjected to myocardial ischemia-reperfusion injury
Comparison
Epigallocatechin gallate (EGCG) vs ferroptosis inhibitors (ferrostatin-1, deferoxamine) in I/R models
Design
In vitro H9c2 cardiomyocyte and in vivo rat coronary artery ligation I/R models
Answers are grounded in this paper and cite their sources.
Does not support EGCG use in clinical I/R injury; hypothesis-generating for PHD2/HIF-1α modulation in ferroptosis.
Objective To investigate whether epigallocatechin gallate (EGCG) alleviates myocardial ischemia-reperfusion (I/R) injury via regulating ferroptosis and further elucidate the underlying mechanism. Methods I/R models were established in H9c2 cardiomyocytes in vitro and in rats via coronary artery ligation in vivo . Lentiviral transfection was conducted in H9c2 cardiomyocytes, and transcriptome sequencing was performed using rat myocardial tissues. Cell viability, ferroptosis-related indicators (Fe 2+ , LDH, GSH, MDA), and the expression of key proteins (SLC7A11, FTH1, GPX4, ACSL4, PHD2, HIF-1α) were detected. Myocardial injury was assessed using TTC staining, HE staining and transmission electron microscopy. Results In H9c2 cardiomyocytes, EGCG produced effects comparable to ferroptosis inhibitors (ferrostatin-1 (Fer-1), deferoxamine (DFO)), reversing Erastin/RSL3 - triggered cell death, enhancing cell viability and diminishing ROS and Fe 2+ accumulation. In the setting of myocardial I/R, these interventions improved cell viability, lowered MDA levels, reduced infarct size and alleviated mitochondrial injury ( P < 0.05). Consistent downregulation of SLC7A11, FTH1 and GPX4 following I/R was observed in both H9c2 cardiomyocytes with simulated I/R and rat myocardium with in vivo I/R ( P < 0.05), and treatment with EGCG, Fer-1 or DFO restored the expression of these proteins in both models. In rat myocardium, I/R upregulated ACSL4, and this elevation was suppressed by EGCG, Fer-1 and DFO. By contrast, only high-dose EGCG inhibited ACSL4 expression in H9c2 cardiomyocytes subjected to simulated I/R. Iron overload exacerbated I/R-triggered myocardial injury and ferroptosis, and EGCG pretreatment alleviated such deterioration ( P < 0.05). Mechanistically, I/R upregulated PHD2 while suppressing HIF-1α and FTH1 expression ( P < 0.05). EGCG pretreatment reversed these I/R-induced alterations, whereas PHD2 overexpression or HIF-1α knockdown abolished the cardioprotective effects of EGCG ( P < 0.05). Conclusion Our findings demonstrate that EGCG alleviates myocardial I/R injury and suppresses ferroptosis by tuning iron homeostasis and the PHD2/HIF-1α signalling cascade.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: